Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to shrink fatty liver in 12 weeks

NCT ID NCT07308548

Recruiting now Disease control Sponsor: Hinova Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 10 times

Summary

This study tests an experimental pill called HP515 for people with non-alcoholic fatty liver disease (NAFLD). About 80 adults with at least 10% liver fat will take the drug for 12 weeks. The main goal is to see if it reduces liver fat measured by MRI, while also checking safety and how the body processes the drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NAFLD (NON-ALCOHOLIC FATTY LIVER DISEASE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Tsinghua Changgung Hospital

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, 102218, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Chengdu Seventh People's Hospital

    RECRUITING

    Chengdu, Sichuan, 610041, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

NAFLD (NON-ALCOHOLIC FATTY LIVER DISEASE)